InDex Pharmaceuticals – Presentation of Q3 quarterly results

InDex Pharmaceuticals – Presentation of Q3 quarterly results

InDex Pharmaceuticals – Presentation of Q3 quarterly results 24 NovemberNov 2021 11:00 - 11:30Online Event

InDex Pharmaceuticals and CEO Peter Zerhouni present highlights from Q3 report and CMO Thomas Knittel deep dives into previous clinical results on cobitolimod.

InDex Pharmaceuticals AB is a development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate #cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex Pharmaceuticals AB has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

Disclaimer: HC Andersen Capital receives payment from InDex Pharmaceuticals for a Digital IR / Corporate Visibility subscription agreement.

Information

InDex Pharmaceuticals – Presentation of Q3 quarterly results 24 NovemberNov 2021 11:00 - 11:30
InDex Pharmaceuticals – Presentation of Q3 quarterly results Online Event